Showing 4321-4330 of 7767 results for "".
- Morgan Dermatology to Expand with Financing from TD Bankhttps://practicaldermatology.com/news/morgan-dermatology-to-expand-with-financing-from-td-bank/2461058/Morgan Dermatology is expanding, thanks to a $1.38 million term loan and $5.26 million Commercial Real Estate Mortgage (CREM) from
- Light Therapy Fast-tracks Healing of Skin Damage from Brachytherapyhttps://practicaldermatology.com/news/light-therapy-fast-tracks-healing-of-skin-damage-from-brachytherapy/2461055/Light therapy may accelerate the healing of skin damage from radiation therapy by up to 50 percent, according to a recent University at Buffalo-led study. Photobiomodulation – a form of low-dose light therapy –lowered the severity of skin damage from radionecrosis, reduced i
- New Analysis Ranks Tremfya Highest Among PsA Treatments for Skin Clearancehttps://practicaldermatology.com/news/new-analysis-ranks-tremfya-highest-among-psa-treatments-for-skin-clearance/2461054/Tremfya® (guselkumab) ranks highest for skin clearance, based on Psoriasis (PsO) Area Severity Index (PASI) 90 response, among 23 psoriatic arthritis (PsA) treatment regimens, results of a newly reported Network Meta-Analysis (NMA) show. In terms of joint inflammation
- UCB Releases Positive Top-line Results for Bimekizumab in Second Phase 3 Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/ucb-releases-positive-top-line-results-for-bimekizumab-in-second-phase-3-psoriatic-arthritis-study/2461047/UCB’s bimekizumab performed well in a Phase 3 study of active psoriatic arthritis patients who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. Significantly more patients treated with bimekizumab achieved 50 percent or great
- Survey Reveals Impact of AGA on Affected Men, Interest in New Therapieshttps://practicaldermatology.com/news/survey-reveals-impact-of-aga-on-affected-men-interest-in-new-therapies/2461046/Nearly two-thirds (64%) of men with androgentic alopecia (AGA) say the condition has a negative affect on their lives, yet more than half (56%) have never sought treatment for the condition, results of a survey show. Findings from the survey, conducted on behalf of
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- BTL Introduces EMFACE Technologyhttps://practicaldermatology.com/news/btl-introduces-emface-technology/2461033/Described as the result of many years of institutional knowledge of the simultaneous emission of radio frequency and electromagnetic energies, EMFACE™ is the newest innovation from BTL. It utilizes a patented technology of muscle contraction and skin tissue heating. &quo
- Cybersecurity Firm Offers Tips to Protect Dermatology Practice Datahttps://practicaldermatology.com/news/cybersecurity-firm-offers-tips-to-protect-dermatology-practice-data/2461029/Ransomware attacks continue to target the healthcare sector. Black Talon Security, a leading NY-based national cybersecurity firm, offers 10 tips that all dermatology practices should follow to keep data secure and protect patient r
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k